Fas Ligand fusion protein

A protein comprising the human Fas Ligand protein (hFasL) or a truncated human Fas Ligand protein or a functionally equivalent variant thereof that retain the Fas receptor-binding and apoptosis-inducing properties of hFasL and, linked either directly or indirectly to its C-terminus, a glycophospholi...

Full description

Saved in:
Bibliographic Details
Main Author THOMAS BUEHLER
Format Patent
LanguageEnglish
Published 15.05.1998
Edition6
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A protein comprising the human Fas Ligand protein (hFasL) or a truncated human Fas Ligand protein or a functionally equivalent variant thereof that retain the Fas receptor-binding and apoptosis-inducing properties of hFasL and, linked either directly or indirectly to its C-terminus, a glycophospholipid is useful in preventing or treating tissue or organ graft rejection.
Bibliography:Application Number: ZA19960009623